Improving the Prescribing Quality and Pattern of Pharmaceutical Drugs in Lebanon

dc.contributor.authorEl-Jardali, Fadi
dc.contributor.authorAbou Samra, Clara
dc.contributor.authorFadlallah, Racha
dc.contributor.authorAkl, Elie
dc.contributor.departmentKnowledge to Policy Center
dc.date.accessioned2025-02-26T07:31:19Z
dc.date.available2025-02-26T07:31:19Z
dc.date.issued2016-10
dc.descriptionK2P Policy Briefs bring together global research evidence, local evidence and context-specific knowledge to inform deliberations about health policies and programmes. It is prepared by synthesising and contextualizing the best available evidence about the problem and viable solutions through the involvement of content experts, policymakers and stakeholders.en_US
dc.descriptionIncludes bibliographical references (pages 38-46)
dc.descriptionArabic version: تحسين جودة ونمط وصف الأدوية في لبنان http://hdl.handle.net/10938/34810
dc.description.abstractIn Lebanon, prescription pharmacological medications inappropriately raises healthcare expenses, puts patient safety at serious risk, and fuels drug resistance. There are insufficient safeguards in the current healthcare system to encourage sensible medication prescriptions. A comprehensive strategy incorporating multi-level interventions is required to address this problem. At the regulatory level, laws should control how medical professionals deal with the pharmaceutical business and guarantee the quality of all medications on the market, even generic versions. Appropriate prescribing can be encouraged at the organisational level through the use of clinical pharmacy services, prescription audits, standardised clinical guidelines, and antimicrobial stewardship initiatives. Academic detailing, problem-based pharmacotherapy training, and conflict of interest education are essential at the professional level. Encouraging patients to take their drugs as prescribed is also crucial to tackling the problem. Time and money limits for clinician education, as well as opposition from organisations that depend on industry financing, are obstacles to adoption. Improving prescribing quality and lowering the related health risks and financial costs on patients and society will require addressing these issues with focused measures at every level.en_US
dc.description.sponsorshipSupported by the Knowledge to Policy Center and the Ministry of Public Health.en_US
dc.description.sponsorshipK2P Center appreciates the collaboration and the contribution of the Center for Systematic Reviews of Health Policy and Systems Research (SPARK) at AUB.
dc.identifier.citationEl-Jardali, F., Fadlallah, R., Abou Samra, C., Akl, E. K2P Policy Brief: Improving the Prescribing Quality and Pattern of Pharmaceutical Drugs in Lebanon. Knowledge to Policy (K2P) Center, Beirut, Lebanon, October, 2016.en_US
dc.identifier.urihttp://hdl.handle.net/10938/34809
dc.language.isoenen_US
dc.publisherKnowledge to Policy Centeren_US
dc.relation.ispartofseriesK2P Policy Brief;
dc.subject.keywordsPharmaceutical Drugs
dc.subject.lcshDrugs--Prescribing--Lebanon
dc.subject.lcshMedical care--Lebanon
dc.titleImproving the Prescribing Quality and Pattern of Pharmaceutical Drugs in Lebanonen_US
dc.typePolicyen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
k2p_PolicyBrief_2016_ImprovingPrescribingQuality.pdf
Size:
805.87 KB
Format:
Adobe Portable Document Format
Description:
Policy Brief

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.65 KB
Format:
Item-specific license agreed upon to submission
Description: